Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

In the present study, we aimed to provide evidence from high-quality real world studies for a
comprehensive and rigorous analysis on the gastrointestinal bleeding (GIB) risk for non …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver
efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …

Background Establishing the appropriate rivaroxaban dose in older patients with non-
valvular atrial fibrillation (NVAF) is important because of the high risk of adverse events. In …

Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …